Lincoln [LINCOLN] vs Unichem Laboratories [UNICHEMLAB] Detailed Stock Comparison
Lincoln
NSE
Loading...
Unichem Laboratories
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Lincoln wins in 12 metrics, Unichem Laboratories wins in 6 metrics, with 0 ties. Lincoln appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Lincoln | Unichem Laboratories | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 12.54 | 29.09 | Lincoln |
| Price-to-Book Ratio | 1.61 | 1.48 | Unichem Laboratories |
| Debt-to-Equity Ratio | 0.00 | 18.76 | Lincoln |
| PEG Ratio | 0.74 | -0.14 | Unichem Laboratories |
| EV/EBITDA | 8.64 | 17.02 | Lincoln |
| Profit Margin (TTM) | 13.71% | 5.80% | Lincoln |
| Operating Margin (TTM) | 13.19% | -1.77% | Lincoln |
| EBITDA Margin (TTM) | 13.19% | N/A | N/A |
| Return on Equity | 12.26% | 5.61% | Lincoln |
| Return on Assets (TTM) | 10.33% | 3.85% | Lincoln |
| Free Cash Flow (TTM) | $737.71M | $-1.44B | Lincoln |
| Dividend Yield | 0.31% | N/A | N/A |
| 1-Year Return | -23.28% | -12.46% | Unichem Laboratories |
| Price-to-Sales Ratio (TTM) | 1.72 | 1.69 | Unichem Laboratories |
| Enterprise Value | $8.89B | $40.90B | Unichem Laboratories |
| EV/Revenue Ratio | 1.41 | 1.90 | Lincoln |
| Gross Profit Margin (TTM) | 54.96% | 53.47% | Lincoln |
| Revenue per Share (TTM) | $315 | $307 | Lincoln |
| Earnings per Share (Diluted) | $43.13 | $17.70 | Lincoln |
| Beta (Stock Volatility) | 0.20 | -0.15 | Unichem Laboratories |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Lincoln vs Unichem Laboratories Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Lincoln | -0.84% | -0.92% | 0.57% | -1.19% | 4.25% | -36.62% |
| Unichem Laboratories | -0.63% | 0.83% | -18.41% | -16.40% | -16.03% | -30.92% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Lincoln | -23.28% | 87.96% | 128.00% | 152.42% | 152.42% | 152.42% |
| Unichem Laboratories | -12.46% | 58.56% | 101.03% | 78.84% | 176.96% | 452.89% |
Performance & Financial Health Analysis: Lincoln vs Unichem Laboratories
| Metric | LINCOLN | UNICHEMLAB |
|---|---|---|
| Market Information | ||
| Market Cap | ₹10.84B | ₹36.31B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 44,670 | 34,186 |
| 90 Day Avg. Volume | 217,249 | 63,628 |
| Last Close | ₹538.65 | ₹503.80 |
| 52 Week Range | ₹499.00 - ₹979.50 | ₹483.00 - ₹937.95 |
| % from 52W High | -45.01% | -46.29% |
| All-Time High | ₹979.50 (Dec 09, 2024) | ₹937.95 (Nov 04, 2024) |
| % from All-Time High | -45.01% | -46.29% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.05% | 0.18% |
| Quarterly Earnings Growth | 0.17% | 0.18% |
| Financial Health | ||
| Profit Margin (TTM) | 0.14% | 0.06% |
| Operating Margin (TTM) | 0.13% | -0.02% |
| Return on Equity (TTM) | 0.12% | 0.06% |
| Debt to Equity (MRQ) | 0.00 | 18.76 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹335.40 | ₹348.07 |
| Cash per Share (MRQ) | ₹97.95 | ₹12.72 |
| Operating Cash Flow (TTM) | ₹967.87M | ₹-1,166,300,000 |
| Levered Free Cash Flow (TTM) | ₹823.46M | ₹1.38B |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.31% | N/A |
| Last 12-Month Dividend | ₹1.80 | ₹0.00 |
Valuation & Enterprise Metrics Analysis: Lincoln vs Unichem Laboratories
| Metric | LINCOLN | UNICHEMLAB |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 12.54 | 29.09 |
| Forward P/E | N/A | N/A |
| PEG Ratio | 0.74 | -0.14 |
| Price to Sales (TTM) | 1.72 | 1.69 |
| Price to Book (MRQ) | 1.61 | 1.48 |
| Market Capitalization | ||
| Market Capitalization | ₹10.84B | ₹36.31B |
| Enterprise Value | ₹8.89B | ₹40.90B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.41 | 1.90 |
| Enterprise to EBITDA | 8.64 | 17.02 |
| Risk & Other Metrics | ||
| Beta | 0.20 | -0.15 |
| Book Value per Share (MRQ) | ₹335.40 | ₹348.07 |
Financial Statements Comparison: Lincoln vs Unichem Laboratories
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | LINCOLN | UNICHEMLAB |
|---|---|---|
| Revenue/Sales | ₹1.68B | ₹5.27B |
| Cost of Goods Sold | ₹801.52M | ₹2.45B |
| Gross Profit | ₹880.31M | ₹2.82B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹234.93M | ₹-93.00M |
| EBITDA | ₹198.39M | ₹293.10M |
| Pre-Tax Income | ₹162.47M | ₹-90.20M |
| Income Tax | ₹46.72M | ₹14.50M |
| Net Income (Profit) | ₹115.75M | ₹-104.70M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | LINCOLN | UNICHEMLAB |
|---|---|---|
| Cash & Equivalents | ₹134.14M | ₹895.80M |
| Total Current Assets | ₹5.00B | ₹20.29B |
| Total Current Liabilities | ₹1.06B | ₹9.92B |
| Long-Term Debt | N/A | ₹860.00M |
| Total Shareholders Equity | ₹6.72B | ₹24.51B |
| Retained Earnings | N/A | ₹24.56B |
| Property, Plant & Equipment | ₹1.82B | ₹12.79B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | LINCOLN | UNICHEMLAB |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | ₹-5.07B |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | LINCOLN | UNICHEMLAB |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 44,670 | 34,186 |
| Average Daily Volume (90 Day) | 217,249 | 63,628 |
| Shares Outstanding | 20.03M | 70.41M |
| Float Shares | 8.79M | 20.17M |
| % Held by Insiders | 0.55% | 0.71% |
| % Held by Institutions | 0.01% | 0.10% |
Dividend Analysis & Yield Comparison: Lincoln vs Unichem Laboratories
| Metric | LINCOLN | UNICHEMLAB |
|---|---|---|
| Last 12-Month Dividend | ₹1.80 | ₹0.00 |
| Last 12-Month Dividend Yield | 0.31% | N/A |
| 3-Year Avg Annual Dividend | ₹1.60 | ₹1.33 |
| 3-Year Avg Dividend Yield | 0.35% | 1.34% |
| 3-Year Total Dividends | ₹4.80 | ₹4.00 |
| Ex-Dividend Date | Sep 13, 2024 | Aug 01, 2022 |